Brief: Vertex announces broad reimbursement agreement With NHS England for Alyftrek for the treatment of cystic fibrosis
15/07/2025 24:03
July 15 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES BROAD REIMBURSEMENT AGREEMENT WITH NHS ENGLAND FOR ALYFTREK® (DEUTIVACAFTOR/TEZACAFTOR/VANZACAFTOR) AN INNOVATIVE ONCE-DAILY CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS Source text: ID:nBwbZXs74a Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria